Back to Search Start Over

COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data

Authors :
Claudia Diniz Lopes, Marques
Sandra Lúcia Euzébio, Ribeiro
Cleandro P, Albuquerque
Samia Araujo, de Sousa Studart
Aline, Ranzolin
Nicole Pamplona Bueno, de Andrade
Andrea T, Dantas
Guilherme D, Mota
Gustavo G, Resende
Adriana O, Marinho
Danielle, Angelieri
Danieli, Andrade
Francinne M, Ribeiro
Felipe, Omura
Nilzio A, Silva
Laurindo, Rocha Junior
Danielle E, Brito
Diana C, Fernandino
Michel A, Yazbek
Mariana P G, Souza
Antonio Carlos, Ximenes
Ana Silvia S, Martins
Glaucio Ricardo W, Castro
Lívia C, Oliveira
Ana Beatriz S B, Freitas
Adriana M, Kakehasi
Ana Paula M, Gomides
Edgard Torres, Reis Neto
Gecilmara S, Pileggi
Gilda A, Ferreira
Licia Maria H, Mota
Ricardo M, Xavier
Marcelo, de Medeiros Pinheiro
Source :
Advances in Rheumatology. 62
Publication Year :
2022
Publisher :
Springer Science and Business Media LLC, 2022.

Abstract

Objectives To evaluate the disease activity before and after COVID-19 and risk factors associated with outcomes, including hospitalization, intensive care unit (ICU) admission, mechanical ventilation (MV) and death in patients with spondylarthritis (SpA). Methods ReumaCoV Brazil is a multicenter prospective cohort of immune-mediated rheumatic diseases (IMRD) patients with COVID-19 (case group), compared to a control group of IMRD patients without COVID-19. SpA patients enrolled were grouped as axial SpA (axSpA), psoriatic arthritis (PsA) and enteropathic arthritis, according to usual classification criteria. Results 353 SpA patients were included, of whom 229 (64.9%) were axSpA, 118 (33.4%) PsA and 6 enteropathic arthritis (1.7%). No significant difference was observed in disease activity before the study inclusion comparing cases and controls, as well no worsening of disease activity after COVID-19. The risk factors associated with hospitalization were age over 60 years (OR = 3.71; 95% CI 1.62–8.47, p = 0.001); one or more comorbidities (OR = 2.28; 95% CI 1.02–5.08, p = 0.001) and leflunomide treatment (OR = 4.46; 95% CI 1.33–24.9, p = 0.008). Not having comorbidities (OR = 0.11; 95% CI 0.02–0.50, p = 0.001) played a protective role for hospitalization. In multivariate analysis, leflunomide treatment (OR = 8.69; CI = 95% 1.41–53.64; p = 0.023) was associated with hospitalization; teleconsultation (OR = 0.14; CI = 95% 0.03–0.71; p = 0.01) and no comorbidities (OR = 0.14; CI = 95% 0.02–0.76; p = 0.02) remained at final model as protective factor. Conclusions Our results showed no association between pre-COVID disease activity or that SARS-CoV-2 infection could trigger disease activity in patients with SpA. Teleconsultation and no comorbidities were associated with a lower hospitalization risk. Leflunomide remained significantly associated with higher risk of hospitalization after multiple adjustments.

Details

ISSN :
25233106
Volume :
62
Database :
OpenAIRE
Journal :
Advances in Rheumatology
Accession number :
edsair.doi.dedup.....a8c4b183c879cda7a1ac579fb50edf54
Full Text :
https://doi.org/10.1186/s42358-022-00268-x